First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional safety analyses from the TROPION-Breast02 study
. Traina T. 12/09/25; 4192132; PS5-03-05
Topic: Other
CLICK HERE TO LOGIN
REGULAR CONTENT
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Rate & Comment (0)
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}